SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Share Price
Equities
002864
CNE1000032C9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.62 CNY | +0.41% |
|
-3.20% | -30.84% |
| Sales 2022 | 974M 134M 10.62B | Sales 2023 | 981M 135M 10.69B | Capitalization | 4.05B 557M 44.1B |
|---|---|---|---|---|---|
| Net income 2022 | 101M 13.91M 1.1B | Net income 2023 | 110M 15.15M 1.2B | EV / Sales 2022 | 3 x |
| Net cash position 2022 | 396M 54.58M 4.32B | Net cash position 2023 | 999M 138M 10.89B | EV / Sales 2023 | 3.11 x |
| P/E ratio 2022 |
33.2
x | P/E ratio 2023 |
34.1
x | Employees | 864 |
| Yield 2022 |
0.52% | Yield 2023 |
0.57% | Free-Float | 57.68% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.41% | ||
| 1 week | -3.20% | ||
| Current month | -8.68% | ||
| 1 month | -9.82% | ||
| 3 months | -13.49% | ||
| 6 months | -28.84% | ||
| Current year | -30.84% |
1 week
26.10
28.03
1 month
26.1030.18
Current year
22.0040.50
1 year
22.0045.73
3 years
21.4376.66
5 years
21.0076.66
10 years
12.0481.36
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Lin Xie
CEO | Chief Executive Officer | 56 | 15/06/13 |
Feng Ming Zhu
DFI | Director of Finance/CFO | 53 | 15/06/13 |
Jie Wu
BRD | Director/Board Member | 54 | 15/06/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Hong Zhang
BRD | Director/Board Member | 60 | 15/06/13 |
Jie Wu
BRD | Director/Board Member | 54 | 15/06/13 |
Xiao Lin Xie
CEO | Chief Executive Officer | 56 | 15/06/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 26.62 | +0.41% | 909,650 |
| 20/06/24 | 26.51 | -1.89% | 1,090,100 |
| 19/06/24 | 27.02 | -1.21% | 1,401,100 |
| 18/06/24 | 27.35 | -0.83% | 1,149,038 |
| 17/06/24 | 27.58 | +0.29% | 1,189,600 |
End-of-day quote Shenzhen S.E., June 20, 2024
More quotes
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent drugs. The Company's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The Company also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The Company is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.84% | 386M | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- 002864 Stock
